What is Phylos Bioscience?
Phylos Bioscience stands as a global leader in cannabis genomics, leveraging advanced molecular genetics and computational biology. The company is dedicated to enhancing hemp and drug varieties for superior performance across various agricultural settings. Its comprehensive suite of genetic testing solutions supports research and development, global breeding partnerships, and cultivation businesses worldwide, positioning Phylos at the forefront of agricultural innovation in the cannabis sector.
How much funding has Phylos Bioscience raised?
Phylos Bioscience has raised a total of $16M across 3 funding rounds:
Private Equity
$1.4M
Unspecified
$7.6M
Debt
$7M
Private Equity (2015): $1.4M, investors not publicly disclosed
Unspecified (2022): $7.6M led by Merida Capital Holdings, Entourage Effect Capital, and Accomplice
Debt (2024): $7M supported by OrganiGram
Key Investors in Phylos Bioscience
OrganiGram
OrganiGram is a Canadian cannabis producer focused on high-quality indoor-grown cannabis for recreational and medical consumers, with a strategy for international business partnerships and brand development.
Merida Capital Holdings
Merida Capital Holdings is an investment firm that typically focuses on the cannabis industry, providing capital for companies in the sector.
Entourage Effect Capital
Entourage Effect Capital is a venture capital firm known for investing in the cannabis and ancillary industries.
What's next for Phylos Bioscience?
With substantial backing, Phylos Bioscience is poised for accelerated growth and expanded market penetration. The enterprise-level financing suggests a strategic focus on scaling operations, further developing its proprietary genomic technologies, and potentially exploring new market segments or international expansion. This capital infusion will likely fuel continued innovation in breeding and genetic testing, solidifying Phylos's leadership in the rapidly evolving cannabis industry.
See full Phylos Bioscience company page
